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Prostaglandin E2 promotes Th1 differentiation
via synergistic ampliﬁcation of IL-12 signalling
by cAMP and PI3-kinase
Chengcan Yao1,2,w, Takako Hirata1,2, Kitipong Soontrapa1, Xiaojun Ma1, Hiroshi Takemori3 & Shuh Narumiya1,2
T helper 1 (Th1) cells have critical roles in various autoimmune and proinﬂammatory diseases.
cAMP has long been believed to act as a suppressor of IFN-g production and Th1 cell-
mediated immune inﬂammation. Here we show that cAMP actively promotes Th1 differ-
entiation by inducing gene expression of cytokine receptors involved in this process. PGE2
signalling through EP2/EP4 receptors mobilizes the cAMP-PKA pathway, which induces
CREB- and its co-activator CRTC2-mediated transcription of IL-12Rb2 and IFN-gR1. Mean-
while, cAMP-mediated suppression of T-cell receptor signalling is overcome by simultaneous
activation of PI3-kinase through EP2/EP4 and/or CD28. Loss of EP4 in T cells restricts
expression of IL-12Rb2 and IFN-gR1, and attenuates Th1 cell-mediated inﬂammation in vivo.
These ﬁndings clarify the molecular mechanisms and pathological contexts of cAMP-medi-
ated Th1 differentiation and have clinical and therapeutic implications for deployment of
cAMP modulators as immunoregulatory drugs.
DOI: 10.1038/ncomms2684 OPEN
1 Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto 606 8501, Japan. 2 Core Research for Evolutional Science and Technology
(CREST), Japan Science and Technology Agency (JST), Tokyo 102 0075, Japan. 3 Laboratory of Cell Signaling and Metabolic Disease, National Institute of
Biomedical Innovation, Osaka 567 0085, Japan. w Present address: MRC Centre for Inﬂammation Research, Queen’s Medical Research Institute, University of
Edinburgh, Edinburgh EH16 4TJ, United Kingdom. Correspondence and requests for materials should be addressed to S.N.
(email: snaru@mfour.med.kyoto-u.ac.jp).
NATURE COMMUNICATIONS | 4:1685 | DOI: 10.1038/ncomms2684 |www.nature.com/naturecommunications 1
& 2013 Macmillan Publishers Limited. All rights reserved.
T
helper (Th) 1 cells have critical roles in various
inﬂammatory immune diseases. Differentiation of naive
T cells to Th1 cells is driven by two critical cytokines,
interleukin (IL)-12 and interferon (IFN)-g, the former derived
from antigen-presenting cells and the latter mainly from T cells,
at the beginning, on T-cell receptor (TCR) stimulation1. Another
cytokine produced on TCR activation, IL-2, is also important in
the early stage of Th1 differentiation2. TCR ligation initiates
activation of Lck and recruitment of ZAP-70 to the TCR complex
to generate multiple downstream signals, resulting in the
production of cytokines including IL-2 and IFN-g, upregulation
of cell surface molecules such as CD25, and induction of
transcription factors for differentiation of Th cells such as T-bet3.
Prostaglandin E2 (PGE2)-cyclic adenosine monophosphate
(cAMP) signalling has long been believed to act as a potent
negative regulator of T cells, especially Th1 cells, and is thought to
mediate inhibition of immune inﬂammation in vivo4–8. It was
reported that cAMP inhibits almost all pathways downstream of
TCR stimulation and suppresses T cell activation, proliferation and
cytokine production8. In contrast to this long-believed prevailing
view, we and others previously reported that PGE2 facilitates
IL-12-driven Th1 differentiation through its receptor EP2 and EP4
(refs 9,10), the major downstream signalling of which is a rise in
cAMP11, and that this PGE2 action operates in vivo in various
mouse models of immune inﬂammation, such as experimental
allergic encephalomyelitis, contact hypersensitivity (CHS), and
collagen-induced arthritis. Consistently, genome-wide association
studies have revealed that the PTGER4 (encoding human EP4)
gene is associated with multiple sclerosis and Crohn’s disease
(CD)12–14, where the association with IL12RB2 (human IL-12Rb2),
a marker of Th1 cells, was also found14,15. Furthermore, a recent
study shows that T cells deﬁcient in Gas and, therefore, incapable
of producing cAMP, display impaired Th1 differentiation and fail
to induce an inﬂammatory response16. While these studies suggest
that PGE2-cAMP signaling promotes rather than suppresses
development of Th1 cells, there are several issues remain to be
answered. For example, (1) how is this cAMP action reconciled
with its inhibitory effects demonstrated by many previous studies,
(2) what is the molecular mechanism whereby cAMP promotes
Th1 development and, (3) what is the pathophysiological context
in which this cAMP action is used?
cAMP activates protein kinase A (PKA) and induces
phosphorylation of the transcription factor cAMP responsive
element (CRE)-binding protein (CREB) at Ser133. Phosphory-
lated CREB binds to CRE-containing promoter and initiates gene
transcription, usually with its coactivator CREB-binding protein/
p300 (ref. 17). CREB-dependent gene expression is also promoted
by another family of coactivators named cAMP-regulated
transcriptional coactivator (CRTC) that binds to CREB in
phospho-Ser133-dependent and -independent manners18,19.
Among the three members of the CRTC family, CRTC2 is
present in abundance in the liver18, spleen and lymph nodes
(http://biogps.gnf.org/). Under the basal conditions, CRTC2 is
phosphorylated at Ser171 by salt-inducible kinase (SIK)20, and
sequestered in the cytoplasm. PKA phosphorylates SIK in the
C-terminal regulatory domain and inhibits its CRTC kinase
activity, which triggers CRTC dephosphorylation and nuclear
translocation21. While the SIK-CRTC pathway has been shown to
be crucial for such physiological processes as gluconeogenesis,
neuronal survival and melanogenesis18,19,22, its function in
T-cell-mediated immune response has never been reported.
IL-12 and IFN-g act on their cognate receptors to drive
differentiation of Th1 cells from naive T cells1. The IL-12 receptor
is composed of two subunits, b1 and b2 chains (IL-12Rb1
and b2), among which the latter is induced speciﬁcally during
Th1 differentiation23,24 and is responsible for IL-12 signal
transduction25. However, its expression mechanism is not known
in detail. Moreover, although naive T cells express both subunits of
IFN-g receptor, a and b chains (IFN-gR1 and R2), IFN-gR1 is
downregulated shortly after TCR engagement in vitro26. Whether
there is any signal counteracting this downregulation of IFN-gR1
by TCR or directly inducing IFN-gR1 expression is currently
unknown. Such a signal, if present, may be important, because the
downregulation of IFN-gR1 may restrict IFN-g signalling, which is
essential for induction of Th1-lineage-speciﬁc transcription factor
T-bet and IL-12Rb2 in the early stage of Th1 differentiation27.
Here we demonstrate that cAMP promotes Th1 differentiation
through upregulation of IL-12Rb2 and IFN-gR1 and the
ampliﬁcation of these cytokine signalling pathways. PGE2
mobilizes cAMP-PKA cascade, which directly induces gene
expression of IL-12Rb2 and IFN-gR1 through CREB and CRTC2.
Simultaneous activation of PI3K by PGE2 rescues T cells from the
inhibitory effects of cAMP on TCR signalling, and promotes
Th1-facilitative action of cAMP by maintaining, for example,
production of IL-2 and IFN-g and expression of CD25. We
further report that selective disruption of EP4 signalling in T cells
limits expression of the above Th1 cytokine receptors and
attenuates Th1-mediated inﬂammation in vivo.
Results
Induction of IL-12Rb2 in TCR-activated T cells by PGE2. To
clarify how PGE2 facilitates Th1 differentiation, we examined
effects of PGE2 on expression of IFN-g (Ifng), T-bet (Tbx21), and
IL-12Rb2 (Il12rb2), three genes critical for Th1 differentiation, in
T cells cultured under the Th1-priming conditions. PGE2 con-
siderably enhanced expression of Il12rb2 and IfngmRNA from 12
and 48 h, respectively, while enhancement of Tbx21 expression
was not seen until 72 h (Fig. 1a). Enhanced expression of Il12rb2
mRNA at 24 h was mimicked by agonists selective to EP2 (ONO-
AE1-259) or EP4 (ONO-AE1-329) but not by agonists to EP1
(ONO-DI-004) or EP3 (ONO-AE-248) (ref. 28) (Fig. 1b).
Induction of IL-12Rb2 protein by PGE2, EP2 or EP4 agonist
during Th1 differentiation was conﬁrmed by ﬂow cytometry
(Fig. 1c). These data suggested that promotion of Th1
differentiation by PGE2 is likely to be initiated through
induction of IL-12Rb2 via EP2 and EP4 receptors.
At least three cytokine signalling pathways, IL-12, IFN-g and
IL-2, are involved in Th1-priming in the culture system we used.
Given that all of these cytokines have the ability to induce IL-
12Rb2 in T cells2,24,29, we asked whether these cytokines signalling
are involved in PGE2-induced IL-12Rb2 expression. We stimulated
T cells with anti-CD3 and anti-CD28 without exogenous IL-12 and
found that PGE2 still upregulated Il12rb2 mRNA and protein
expression (Fig. 1d,e). Furthermore, blockade of IL-12 signalling by
anti-IL-12 had little effect on the basal or PGE2-induced IL-12Rb2
expression in TCR-activated T cells (Supplementary Fig. S1a).
Blockade of IFN-g (Supplementary Fig. S1b) or both IFN-g and
IL-2 (Supplementary Fig. S1c) signalling by using IFN-gR1 /
T cells30 and anti-IL-2 reduced both the basal IL-12Rb2 expression
and its enhancement by PGE2. However, even without IFN-g and
IL-2 action, PGE2 still exhibited enhancement of IL-12Rb2
expression over the basal level (Supplementary Fig. S1c). EP2
and EP4 agonists again mimicked this action of PGE2 on
expression of IL-12Rb2 mRNA and protein in TCR-activated T
cells (Supplementary Fig. S1d,e), and the induction of Il12rb2
mRNA expression by EP2 or EP4 agonists was defective in EP2- or
EP4-deﬁcient T cells, respectively (Supplementary Fig. S1f), con-
ﬁrming that EP2 and EP4 mediate IL-12Rb2 induction by PGE2.
Involvement of PI3K and cAMP in PGE2-induced IL-12Rb2.
Given that EP2 and EP4 stimulation activates both PI3-kinase
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(PI3K)-Akt and cAMP-PKA pathways9, we examined their
involvement in IL-12Rb2 induction by PGE2. Inhibitors of
PI3K (LY-294002 and wortmannin) partially prevented PGE2-
induced Il12rb2 expression in TCR-activated T cells (Fig. 1f). As
PI3K-Akt pathway mediates TCR-induced production of IFN-g
and IL-2 that have important roles in IL-12Rb2 expression and
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Figure 1 | PGE2-cAMP signalling induces IL-12Rb2 expression in TCR-activated Tcells. (a) Expression of Ifng, Tbx21 and Il12rb2mRNA by Tcells activated
for indicated times with antibody to CD3 and antibody to CD28 (aCD3/CD28) in the absence or presence of PGE2 under Th1-priming conditions. A portion
of cells were restimulated with PMA and ionomycin for the last 4 h (72R). (b) Expression of Ifng, Tbx21 and Il12rb2 mRNA by T cells activated for 24 h
with aCD3/CD28 in the absence or presence of PGE2 or selective agonists to EP1 to EP4 under Th1-priming conditions. (c) Surface expression of IL-12Rb2
in T cells activated for 48 h with aCD3/CD28 in the absence or presence of PGE2 or agonists selective to EP1 to EP4 under Th1-priming conditions. Grey-
ﬁlled histogram represents isotype control. DMFI (mean ﬂuorescence intensity) indicates the differences between MFI of IL-12Rb2 and MFI of isotype
control (right). (d) Time-course of Il12rb2 mRNA expression by PGE2 in Tcells activated with aCD3/CD28. (e) PGE2 induces IL-12Rb2 protein expression in
T cells activated with aCD3/CD28 for 48 h. (f,g) Expression of Il12rb2 mRNA in WT T cells (f) or IFN-gR1–/– T cells supplemented with anti-IL-2
(g), activated for 24 h with aCD3/CD28 in the absence or presence of PGE2 with or without Wortmannin, LY-294002 or H-89. (h) Expression of Il12rb2
mRNA in Tcells activated for 24h with aCD3/CD28 in the absence or presence of PGE2 with H-89, Rp-8-Br-CAMPS or Rp-8-CPT-CAMPS. (i,j) Expression of IL-
12Rb2 mRNA (i) and protein (j) in Tcells activated with aCD3/CD28 in the presence of db-cAMP, forskolin or 3-isobutyl-1- methylxanthine (IBMX) for 12h (i) or
48h (j). (k) Expression of Il12rb2mRNA in IFN-gR1 / CD4þ Tcells activated for 24h with aCD3/CD28 with or without db-cAMP in the absence or presence
of anti-IL-2 or LY-294002 (LY) or both. Data shown as mean±s.e.m. are representative of two or more independent experiments with triplicates. Statistical
signiﬁcance was examined by unpaired two-tailed Student’s t-test, *Po0.05; **Po0.01; ***Po0.001. NS, not signiﬁcant, veh, vehicle; a.u., arbitrary units.
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Th1 differentiation2,31, we examined effects of LY-294002 on
IL-12Rb2 induction in TCR-activated IFN-gR1-deﬁcient T cells
supplemented with anti-IL-2. Under this condition where both
IFN-g and IL-2 signalling were blocked, LY-294002 did not
inhibit PGE2-induced Il12rb2 expression (Fig. 1g). These results
indicate that there are PI3K-dependent and -independent
mechanisms of Il12rb2 induction and the former was
dependent on IFN-g and IL-2. Intriguingly, PKA inhibitors
(H-89, Rp-8-Br-cAMPS or Rp-8-CPT-cAMPS)32 also attenuated
PGE2-induced Il12rb2 expression in TCR-activated wild-type
(WT) T cells (Fig. 1h), and H-89 completely suppressed IL-12Rb2
induction in the absence of IFN-g and IL-2 signalling (Fig. 1g).
Conversely, expression of IL-12Rb2 mRNA and protein was
enhanced by dibutyryl cAMP (db-cAMP) and forskolin (Fig. 1i,j).
Moreover, Il12rb2 mRNA was upregulated by a nonspeciﬁc
phosphodiesterase (PDE) inhibitor 3-isobutyl-1- methylxanthine
(Fig. 1i), suggesting that endogenous cAMP has a role in IL-
12Rb2 expression. Interestingly, cAMP-induced IL-12Rb2
expression in TCR-activated T cells was suppressed partially by
PI3K inhibitors but this suppression was not seen when both
IFN-g and IL-2 signalling were blocked (Fig. 1k).
Direct and indirect induction of IL-12Rb2 by cAMP. As the
above results suggest the involvement of IFN-g and IL-2 in a part
of cAMP-induced Il12rb2 expression by TCR-activated T cells, we
next evaluated how and how much IFN-g and IL-2 contribute to
cAMP-induced Il12rb2 expression by stimulating T cells with or
without TCR activation, with or without IFN-g signalling, and in
the presence or absence of cAMP for 12 h. In WT T cells, while
db-cAMP, IFN-g or TCR activation alone induced Il12rb2
expression at a similar level, cAMP synergistically induced Il12rb2
expression in the presence of IFN-g or TCR or both (Fig. 2a).
Addition of anti-IFN-g did not affect the stimulation by
db-cAMP in unactivated T cells, but blunted cAMP response in
TCR-activated cells. Consistently, none of the above synergistic
effects of IFN-g or TCR with cAMP was seen in IFN-gR1 /
T cells at 12 h (Fig. 2a). Synergistic action of cAMP with IFN-g or
TCR activation on IL-12Rb2 protein expression in T cells was
also conﬁrmed (Fig. 2b). We then evaluated the involvement of
IL-2 signalling in cAMP-induced IL-12Rb2 expression. We used
IFN-gR1 / T cells to exclude the effect of IFN-g signalling.
Although cAMP and TCR signalling had no synergistic action on
Il12rb2 expression in IFN-gR1 / T cells at 12 h (Fig. 2a), we
noted that they synergistically induced Il12rb2 expression after
24 h and this synergistic action was eliminated by anti-IL-2
(Fig. 2c), suggesting that synergistic action on Il12rb2 expression
with TCR activation and cAMP was mediated by IL-2 and this
phenomenon did not appear until 24 h of stimulation. Con-
sistently, blocking either IFN-g or IL-2 signalling downregulated
the basal, as well as the cAMP-induced Il12rb2 expression, and
blocking both further reduced Il12rb2 expression in TCR-
activated WT T cells at 36 h, but cAMP still enhanced Il12rb2
expression over the basal level under these conditions (Fig. 2d).
These results demonstrate that there are direct and indirect
mechanisms of cAMP-promoted Il12rb2 expression, and that
IFN-g and IL-2 are involved in the latter indirect mechanism.
cAMP context-dependently regulates Th1 differentiation. The
above results that cAMP synergizes with IFN-g and IL-2 in
Il12rb2 induction in TCR-activated T cells led us to wonder how
such synergistic effects are elicited by cAMP, because cAMP is
known to suppress production of these cytokines by inhibiting
TCR signalling. We conﬁrmed that cAMP treatment at the
beginning of TCR stimulation indeed strongly suppressed
markers of T-cell activation such as CD25, IL-2 and IFN-g.
However, this inhibitory effect of cAMP could be rescued by
enhancing CD28 costimulation and, intriguingly, this rescue was
repressed by LY-294002 (Fig. 2e). These results suggest that
coactivation of PI3K overcomes the suppression of TCR signal-
ling by cAMP, and allows cAMP to facilitate Il12rb2 expression.
We then asked whether similar coactivation of PI3K could rescue
cAMP inhibition of Th1 differentiation. To this end, we stimu-
lated T cells with anti-CD3 and different concentrations of anti-
CD28 and treated cells with db-cAMP for various periods under
Th1-priming conditions. cAMP-mediated inhibition of Th1 dif-
ferentiation was rescued or overcome by the strengthening CD28
costimulation or by the addition of cAMP at later times after TCR
activation, which avoided cAMP-mediated inhibition on initia-
tion of TCR signalling (Fig. 2f). Moreover, PGE2 did not inhibit
but promoted Th1 differentiation even if it was added into cul-
tures at the beginning of TCR ligation (0 h) at a CD28 costimu-
lation level where cAMP showed an extremely strong inhibitory
effect (Fig. 2f). This could be due to the fact that PGE2 activated
both cAMP and PI3K pathways through EP2 and EP4 in T cells9
and PI3K antagonized cAMP-dependent inhibition of TCR
signalling33. Similarly, cAMP-mediated inhibition of cell
proliferation during Th1 differentiation was also rescued by
strengthening CD28 costimulation or postponing cAMP
treatment (Fig. 2g).
Upregulation of IFN-cR1 and IL-2Rb by cAMP. As the above
ﬁndings suggest that cAMP can induce IL-12Rb2 expression in
T cells partly through IFN-g and IL-2, the next question was how
cAMP ampliﬁed IFN-g and IL-2 signalling. We ﬁrst noted that
the induction of Il12rb2 by cAMP was partially reduced by
treatment of the cells with cycloheximide, suggesting the invol-
vement of new protein synthesis in this process (Fig. 3a). To
identify protein(s) newly synthesized in response to cAMP, we
proﬁled gene expression in TCR-activated WT and IFN-gR1 /
T cells stimulated with or without db-cAMP. Consistent with
previous reports8, cAMP inhibited gene expression of several
cytokines such as Il2, Ifng, Tnf and Lta in TCR-activated T cells
(Fig. 3b). In congruence with our results (Fig. 2a,b), Il12rb2
expression was upregulated by db-cAMP in both WT and
IFN-gR1 / T cells (Fig. 3b), verifying an IFN-g signalling-
independent induction of Il12rb2 by cAMP. Additionally, we
noted enhanced expression of genes encoding receptors for IFN-g
and IL-2, such as Ifngr1 and Il2rb, in T cells (Fig. 3b). We
conﬁrmed by real-time PCR and ﬂow cytometry that cAMP
increased both Ifngr1 mRNA and IFN-gR1 protein expression in
naive T cells (Fig. 3c,d). This action of cAMP was also observed in
TCR-activated T cells, although TCR itself strongly
downregulated IFN-gR1 expression (Fig. 3c,d). IFN-g-induced
STAT1 activation in naive T cells was also enhanced by
pretreatment with db-cAMP, suggesting that cAMP ampliﬁes
IFN-g signalling (Fig. 3e). Similarly, cAMP also upregulated Il2rb
mRNA expression in T cells after 24 h, but not 12 h, stimulation
(Fig. 3f) and upregulation of IL-2Rb protein expression by cAMP
was also conﬁrmed using ﬂow cytometry (Fig. 3g). These data
suggested that cAMP ampliﬁes IFN-g and IL-2 signalling in
T cells through the upregulation of IFN-gR1 and IL-2Rb,
respectively.
Requirement of CREB for cAMP-induced IL-12Rb2 and IFN-
cR1. We next investigated the molecular mechanisms of how
cAMP directly induces IL-12Rb2 and IFN-gR1 expression. The
db-cAMP-induced Il12rb2 and Ifngr1 expression was mimicked
by a PKA-speciﬁc agonist N6-Bnz-cAMP (ref. 34) (Fig. 4a) and
attenuated by PKA inhibitors (Fig. 4b) in unactivated T cells,
which produced neither IL-2 nor IFN-g. We transfected
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unactivated T cells with a small interfering RNA (siRNA) for
Creb1 or a scrambled siRNA and then stimulated T cells with
db-cAMP. Creb1-speciﬁc siRNA reduced CREB expression in
transfected cells (Fig. 4c) and suppressed cAMP-induced Il12rb2
and Ifngr1 expression compared with those in T cells transfected
with scrambled siRNA (Fig. 4d). CREB is usually activated by
phosphorylation at Ser133, p-CREB(S133), which promotes
transcription by recruitment of the coactivator CREB-binding
protein to gene loci17. However, although TCR or phorbol-12-
myristate-13-acetate (PMA) plus ionomycin could induce CREB
activation (Fig. 4e), they did not induce, but rather reduced
Il12rb2 or Ifngr1 expression under the condition where cAMP
induced both mRNAs (Fig. 4f). These results suggest requirement
of other factors downstream of PKA in addition to
p-CREB(S133).
Involvement of CRTC2 in cAMP-induced IL-12Rb2 and IFN-
cR1. One candidate for such factors is CRTC2 that is regulated
negatively by SIK2 and functions as a CREB coactivator in many
types of cells19–22. Stimulation of T cells with db-cAMP induced
not only phosphorylation of CREB but also dephosphorylation of
CRTC2 (Fig. 5a), decreased the amount of CRTC2 in the
cytoplasm and increased the amount of dephosphorylated
CRTC2 in the nucleus (Fig. 5b). This distribution is SIK-
dependent, because SIK2–/– T cells22 constitutively showed more
nuclear CRTC2 than WT cells, which increased little by cAMP
(Fig. 5c). As reported18,19, protein kinase inhibitor staurosporine
(STS) induced dephosphorylation and nuclear translocation of
CRTC2 without enhancing CREB phosphorylation (Fig. 5b). To
investigate whether cAMP affects transcriptional activity of
CRTC2, we performed a reporter assay with GAL4-fusion
CRTC2 in WT and SIK2–/– T cells. While db-cAMP increased
GAL4-transcriptional activity in WT cells, the basal GAL4
activity was already higher in SIK2–/– T cells and no further
increase was observed upon cAMP addition (Fig. 5d). These
ﬁndings suggest that SIK2-CRTC2 pathway functions
downstream of cAMP in T cells.
To corroborate that SIK2-CRTC2 pathway mediates cAMP-
induced expression of Il12rb2 and Ifngr1, we depleted CRTC2 in
T cells by siRNA (Fig. 5e). CRTC2 depletion considerably
suppressed db-cAMP-induced Il12rb2 and Ifngr1 expression
(Fig. 5f). Conversely, STS induced expression of Il12rb2 and
Ifngr1 mRNA as potently as db-cAMP (Fig. 5g). Expression of
Nr4a2, a gene known to be regulated by CRTC2 and p-CREB35,
was also reduced by CRTC2 siRNA and induced by STS and
db-cAMP (Fig. 5f,g), while another p-CREB-target gene Fosb was
induced only by db-cAMP (Fig. 5g), probably reﬂecting
7 Vehicle
db-cAMP
Vehicle
db-cAMP
Vehicle
db-cAMP
Vehicle
db-cAMP
IFN-γR1+/+
Unactivated
Unactivated
Unactivated
– –
–– +
+ +
+
IFN-γ
db-cAMP
100
80
60
40
20
0
2.5
2.0
1.5
1.0
0.5
0.0
ΔM
FI
Vehicle
db-cAMP
TCR
p-STAT1
(Y701)
STAT1
TCR
IFN-γR1–/–6
5
4
4
4
5
2
3
1
0
3
2
1
0
–1
–2
–3
–4
Ifn
gr1
Ifn
gr2
II1
2rb
2
II2
rb
II2
rb
II2
ra
II2
ra
II1
2rb
1
Ifn
g Lta Tn
f II2
3
2
1
0
(–)
Vehicle Vehicle
db-cAMPdb-cAMP
db-cAMP
Vehicle
3
2
1
0
12 h 24 h
TCR
CHX
II1
2r
b2
 
m
R
N
A 
(a.
u.)
II1
2r
b 
m
R
N
A 
(a.
u.)
Ifn
gr
1 
m
R
N
A 
(a.
u.)
IF
N
-γR
1+
 
ce
lls
 (%
)
IFN-γR1
100 101 102 103 100 101 102 103
IL-2Rβ
Fo
ld
-in
du
ct
io
n
(db
-cA
MP
/Ve
hi
cl
e,
 
lo
g 2
)
Figure 3 | cAMP ampliﬁes IFN-c and IL-2 signalling through induction of IFN-cR1 and IL-2Rb. (a) Expression of Il12rb2 mRNA in T cells activated with
aCD3/CD28 for 24 h with addition of db-cAMP or cycloheximide (CHX) or both for the last 12 h. (b) Proﬁle of db-cAMP-dependent expression of
cytokines and their receptors by WT or IFN-gR1 / T cells activated for 12 h with aCD3/CD28 followed by treatment with db-cAMP or vehicle for
another 3 h. Data shown in bar graphs represents fold change (db-cAMP versus vehicle) in mean intensity from each probe in biological duplicates. The
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less CRTC2 contribution35. Consistently, overexpression of a
constitutively active form of CRTC2, CRTC2(S171A), which
could not be phosphorylated at the site Ser171 and, therefore,
retained in the nucleus20, enhanced the basal expression of
Il12rb2 and Ifngr1, while overexpression of a constitutively active
form of SIK2, SIK2(S587A), which constitutively phosphorylated
CRTC2 and thus prevented CRTC2 nuclear translocation36,
suppressed the db-cAMP-induced Il12rb2 and Ifngr1 expression
(Fig. 5h). Furthermore, comparing to WT cells, SIK2–/– T cells
have a higher level of Il12rb2 and Ifngr1 mRNA, which could be
suppressed by overexpression of WT SIK2 or the SIK2(S587A)
mutant (Fig. 5i). These data suggest that CRTC2 mediates cAMP-
PKA signalling-induced expression of Il12rb2 and Ifngr1.
Binding of p-CREB and CRTC2 to Il12rb2 and Ifngr1 gene loci.
Computational analysis identiﬁed several putative half or full
CRE sites in the promoter/enhancer regions of Il12rb2 and Ifngr1
gene loci (Fig. 6a). We performed chromatin immunoprecipi-
tation analysis and observed that upon cAMP stimulation,
p-CREB(S133) and CRTC2 were recruited to several of these sites
located from  3.6 to þ 0.8 kb in Il12rb2 gene locus (Fig. 6b, sites
E–L). Similarly, cAMP increased binding of p-CREB(S133) and
CRTC2 to two sites around the transcription start site and one
site at position þ 4.6 kb in the ﬁrst intron of Ifngr1 gene (Fig. 6c,
sites M, N and P). These results suggest that CREB and CRTC2
activated by cAMP are recruited to the sites in the promoter/
enhancer regions of Il12rb2 or Ifngr1 gene loci.
We cloned a  4.6 kb to þ 70 bp fragment of the Il12rb2
promoter/enhancer region in the pGL4 luciferase reporter vector,
transfected it into EL4 cells and stimulated with db-cAMP or
forskolin. db-cAMP and forskolin induced Il12rb2 promoter
reporter activity (Fig. 6d) and this cAMP-induced Il12rb2 pro-
moter activity was suppressed by treatment with Creb1 siRNA,
overexpression of the CREB(S133A) mutant or Crtc2 siRNA
(Fig. 6e–g), indicating that both p-CREB(S133) and CRTC2
regulate cAMP-activated Il12rb2 transcription.
EP4 signalling in T cells enhances Th1 inﬂammation in vivo.
To study whether PGE2-EP4-cAMP signalling in T cells regulates
cytokine receptors and Th1 response in vivo, we generated mice
with deletion of EP4 in T cells by crossing Lck-Cre mice37 with
EP4-ﬂoxed mice38. Loss of EP4 in CD4þ T cells was conﬁrmed
in Lck-CreþEP4ﬂ/þ and Lck-CreþEP4ﬂ/ﬂ mice (Fig. 7a). To
investigate whether EP4 deﬁciency in T cells affects in vivo Th1
differentiation and expression of Th1-related cytokine receptors,
we used the CHS model and immunized Lck-CreEP4ﬂ/ﬂ or Lck-
CreþEP4ﬂ/ﬂ mice by painting the shaved abdomen with
dinitroﬂuorobenzene (DNFB) on day 0 and puriﬁed CD4þ
T cells in draining lymph nodes (dLNs) on day 5. CD4þ T
cells from Lck-CreþEP4ﬂ/ﬂ mice produced less amounts of IFN-g
and IL-2 (Fig. 7b) and exhibited less mRNA expression of Th1
cytokine receptors, for example, Il12rb2, Ifngr1, Il2rb and CREB/
CRTC2-targeted gene Icer than T cells from littermate control
Lck-CreEP4ﬂ/ﬂ mice (Fig. 7c). Consistent with the above
results, the numbers of IL-12Rb2- and IFN-gR1-expressing
CD4þ T cells in dLNs from Lck-CreþEP4ﬂ/ﬂ mice were also
lower than those from control mice (Fig. 7d). We also found that
Cd69 gene expression and the number of CD4þCD69þ T cells
were decreased in dLNs from DNFB-sensitized Lck-CreþEP4ﬂ/ﬂ
mice (Fig. 7c,d). Moreover, when we adoptively transferred dLN
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mRNA in T cells stimulated with db-cAMP in the presence of PKA inhibitor, Rp-8-Br-cAMPS and/or Rp-8-CPT-cAMPS for 12 h. (c,d) T cells treated
with scrambled or Creb1 siRNA for 48 h, followed by immunoblot for CREB (c) or stimulated with db-cAMP for another 12 h for detection of mRNA
expression (d). mRNA expression is normalized to vehicle-treated of each siRNA-transfected cells. Icer and Nr4a2 were used as positive controls for
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cells from DNFB-sensitized Lck-CreþEP4ﬂ/ﬂ or Lck-CreEP4ﬂ/ﬂ
mice into naive C57BL/6 mice on day 5 and immediately
challenged the recipient mice by painting the same antigen on the
ear, transfer of EP4-deﬁcient T cells induced less ear swelling
(Fig. 7e).
We next isolated CD45RBhiCD25CD4þ naive T cells from
the spleen of Lck-CreþEP4þ /þ or Lck-CreþEP4ﬂ/þ mice,
transferred them into mice deﬁcient in recombination-activating
gene 2 (Rag2–/– mice), and monitored development and
progression of colitis. Transfer of naive T cells of both
genotypes induced colitis in Rag2–/– mice. However, the
transfer of Lck-CreþEP4ﬂ/þ T cells induced milder body
weight loss (Fig. 7f) and weaker colonic inﬂammation than that
of T cells from littermate control Lck-CreþEP4þ /þ mice
(Fig. 7g). Moreover, mesenteric lymph node CD4þ T cells
from Rag2–/– mice reconstituted with Lck-CreþEP4ﬂ/þ T cells
produced less amounts of IFN-g and IL-2 (Fig. 7h) and expressed
lower levels of Il12rb2, Ifngr1, Il2rb, Cd69 and Icer mRNA
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(Fig. 7i) than CD4þ T cells from Rag2–/– mice reconstituted with
Lck-CreþEP4þ /þ T cells. We also repeated this transfer
experiment using CD45RBhiCD25CD4þ naive T cells from
Lck-CreþEP4ﬂ/ﬂ mice or EP2 / mice. We have found
attenuation of the colitis also in the Rag2 / mice
reconstituted with Lck-CreþEP4ﬂ/ﬂ T cells and have not found
any difference of colitis development between the groups of mice
that received WT and EP2 / T cells (data not shown). These
results conﬁrm the importance of EP4 and indicate that EP2 has,
if any, a minor role in T cells, a loss of which can be compensated
for by EP4.
Discussion
Here we have dissected the molecular mechanism underlying
PGE2-induced facilitation of Th1 differentiation, and revealed the
role of cAMP in this process. PGE2 acts on EP2 or EP4 receptors
to generate cAMP and cAMP activates PKA, which in turn
directly phosphorylates CREB and induces dephosphorylation
and nuclear translocation of CRTC2 through inhibiting SIK2.
Activated CREB and CRTC2 together promote gene transcription
of IL-12Rb2 and IFN-gR1, receptors for two critical cytokines of
Th1 differentiation. Our ﬁndings are consistent with recent
reports that PGI2-IP signalling promotes Th1 differentiation
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through cAMP-PKA pathway in vitro and enhances CHS
responses in vivo39, and that Gas-deﬁcient T cells which fail to
produce cAMP, show impaired differentiation into Th1 cells and
that the addition of cAMP analogue restores Th1 differentiation
in these cells16. Our study has thus veriﬁed the facilitative role of
cAMP in Th1 differentiation by clarifying its molecular
mechanism.
A question remains as to how these ﬁndings are reconciled
with the long-held, traditional view that cAMP suppresses Th1
differentiation8. Here we found that cAMP-mediated inhibition
of TCR-induced expression of CD25, production of IL-2 and
IFN-g, Th1 differentiation and cell proliferation could all be
rescued or even overcome by strengthening CD28 costimulation
in a PI3K-dependent manner. Simultaneous activation of PI3K at
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cAMP generation by PGE2-EP2/EP4 signalling9 combined with
that by CD28 costimulation can cancel out the cAMP-mediated
inhibition of TCR signalling, and preserve, for example,
expression of critical genes such as CD25, IL-2 and IFN-g. The
primary inhibitory site by cAMP may be Lck. Tasken and his
collaborators suggested that PKA interferes with LCK activation,
and this action can be antagonized by PI3K activation following
CD28 costimulation33,40.
Then, how important is this PGE2-cAMP-dependent mechanism
in Th1-mediated immune response in vivo and in human
immune diseases? Here we have used two disease models and
demonstrated that EP4-cAMP signalling in T cells facilitated
expression of Th1 cytokine receptors and Th1 response in vivo.
We have generated mice with selective deletion of EP4 in T cells,
and revealed that the loss of EP4 in T cells considerably
attenuates CHS response and the adoptive transfer colitis. In both
models, selective blockade of EP4 in T cells prevented in vivo Th1
differentiation with downregulated expression of Il12rb2, Ifngr1
and Il2rb genes and other CREB/CRTC2-dependent genes in
lymph nodes (LNs) CD4þ T cells. CHS is a mouse model of
allergic contact dermatitis in humans, in which IFN-g produced
by CD4þ Th1 and CD8þ type 1 cytotoxic T cells has an
important role41. The adoptive transfer colitis is a model of
inﬂammatory bowel disease, particularly CD42. Genome-wide
association studies have revealed that the PTGER4, IL12RB2 and
IL2RA (human IL-2Ra) genes are linked to risk loci associated
with CD13,14. High expression of IL12RB2, IL2RA and IL2RB
(encoding human IL-2Rb) genes was found in blood or in lamina
propria CD4þ T cells of patients with CD43,44. Upregulation of
CREB was also found in peripheral blood mononuclear cells from
patients with inﬂammatory diseases including CD45.
Additionally, in experimental allergic encephalomyelitis, a
mouse model for multiple sclerosis, systemic inhibition of EP4
suppressed Th1 differentiation and IFN-g production9,46.
Interestingly, PTGER4 and IL12RB2 were shown to be
associated with multiple sclerosis12,15. Thus, our results showed
that EP4-cAMP signalling in T cells has a critical role in
regulation of cytokine signalling and Th1 response in vivo using
various mouse models of immune inﬂammation and suggest the
possibility of similar actions operating clinically in human
diseases.
Here we have demonstrated how cAMP signalling facilitates
Th1 differentiation, and shown that PGE2-EP4 signalling is
representative of such cAMP signalling operating in T cells.
Figure 8 depicts our model for cAMP-mediated Th1 differentia-
tion and its cross-talk with PI3K pathway in TCR activation. In
addition to prostanoids, there are a number of other agents that
can activate cAMP signalling in T cells, such as catecholamines,
histamine and adenosine8. Our results suggest a possibility that
these substances similarly facilitate Th1 differentiation and
promote immune inﬂammation. This is particularly the case for
those substances that activates both PI3K and cAMP signalling
simultaneously. Given that most of these receptors are G-protein
coupled receptors (GPCRs), our present results show how GPCR
signalling cooperates with cytokine signalling, that is, amplifying
the latter actions by inducing their receptors. We propose to
designate such GPCR actions as cytokine ampliﬁcation and
ligands of such GPCR as cytokine ampliﬁers. This cytokine
amplifying action of GPCR ligands surely accounts for some of
their pathophysiological actions and may, therefore, be of
therapeutic consideration.
Methods
Mice. C57BL/6 mice were obtained from Japan SLC (Shizuoka, Japan). EP2- and
EP4-deﬁcient and littermate control WT mice have been previously described9.
Mice defective in IFN-gR1 on a C57BL/6 background30 were kind gifts from
M. Aguet. To generate EP4-deﬁcient T cells, Lck-Cre mice37 were crossed to
lox-ﬂanked Ptger4 mice38. SIK2 / mice have been described elsewhere22 and
were housed in the National Institute of Biomedical Innovation. All mice, except
the SIK2 / mice, were housed at the Institute of Laboratory Animals of Kyoto
University on a 12-h light/dark cycle under speciﬁc pathogen-free conditions.
All experimental procedures were approved by the Committee on Animal Research
of Kyoto University Faculty of Medicine and National Institute of Biomedical
Innovation.
Plasmids. WT CREB and the CREB(S133A) mutant plasmids were kindly pro-
vided by H. Bito. pGFP-mSIK2, pGFP-mSIK2 S587A, pGFP-mCRTC2 S171A and
GAL4 fused pM-mCRTC2 and pTAL-5x GAL4 have been described16,34.
Reagents. PGE2 (100 nM) was obtained from Cayman Chemical. Agonists
selective to each EP subtype (ONO-DI-004, ONO-AE1-259, ONO-AE-248 and
ONO-AE1-329 for EP1, EP2, EP3 and EP4, respectively, each 100 nM) were kind
gifts of Ono Pharmaceutical Co., Japan. Dibutyryl cAMP (db-cAMP, 100 mM),
N6-Bnz-cAMP (30–300 mM), wortmannin (100 nM), LY-294002 (1 mM), H-89
(10 mM), Rp-8-CPT-cAMPS (300 mM), Rp-8-Br-cAMPS (300 mM), Forskolin
(1 mM) and 3-isobutyl-1-methylxanthine (100 mM) were purchased from Sigma.
Cycloheximide (10 mM) and STS (5–50 nM) were purchased from Calbiochem.
Preparation and culture of CD4þ T cells. Naive CD4þCD45RBþCD25 and
CD4þ T cells were puriﬁed from spleens and LNs by using FACS Aria2 (Becton
Dickinson) and auto-MACS (Miltenyi), respectively. Cells were cultured in com-
plete RPMI1640 medium containing 10% FBS. For in vitro activation of T cells,
plate-bound antibodies to CD3 (10 mgml 1, clone 145-2C11, eBioscience) and
CD28 (10mgml 1 or indicated concentrations, clone 37.51, eBioscience) were
used. For TH1 differentiation, cells were stimulated with anti-CD3 and anti-CD28
for the ﬁrst 2 days, and then without anti-CD3 and anti-CD28 antibodies for
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Figure 8 | A model for synergistic action of cAMP and PI3K in Th1
differentiation. cAMP generated in response to PGE2 binding to EP2/EP4
activates PKA, which phosphorylates CREB and activates CRTC2 through
phosphorylation of SIK. Activated CREB and CRTC2 translocate to the
nucleus and induce expression of Il12rb2, Ifngr1 and possibly Il2rb, thus
facilitating Th1 differentiation synergistically with IL-12, IFN-g and IL-2.
While cAMP-PKA inhibits T-cell activation by suppressing TCR signalling,
coactivation of PI3K by EP2/EP4 and CD28 cancels this inhibition and
promotes the Th1-facilitative action of cAMP.
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another 24 h. Cells were cultured with 2,500Uml 1 rmIL-2, 10 ngml 1 rmIL-12
(R&D Systems) and 5 mgml 1 anti-IL-4 (clone 11B11, eBioscience) for 3 days.
To reduce the background of phosphorylated CREB, freshly isolated CD4þ T cells
were cultured for 2 days in RPMI1640 medium and IL-7 (10 ngml 1, R&D
Systems) that was added to maintain the survival of naive T cells47. In some culture
conditions, 10 ngml 1 of IFN-g (R&D Systems) or 10mgml 1 of anti-mouse
IFN-g (clone XMG1.2, eBioscience), anti-mouse IL-12/IL-23 p40 (clone C17.8,
eBioscience) or anti-mouse IL-2 (clone JES6-1A12, eBioscience) were added.
Surface and intracellular staining. For surface staining, CD4þ T cells were
directly stained with phycoerythrin (PE)-conjugated anti-mouse CD119 (IFN-gR1,
clone 2E2, eBioscience), PE-conjugated rat anti-mouse CD122 (IL-2Rb, clone TM-
b1, BD Pharmingen) or PE-conjugated anti-mouse CD69 (clone H1.2F3,
eBioscience), or stained ﬁrstly with hamster anti-mouse IL-12Rb2 (BD Pharmin-
gen) and then with PE-conjugated mouse anti-Armenian and Syrian hamster IgG
cocktail (BD Pharmingen). For intracellular staining, CD4þ T cells were resti-
mulated with 50 ngml 1 PMA (Sigma) and 500 ngml 1 ionomycin (Sigma) in
the presence of GolgiPlug (BD Pharmingen) for the last 4–5 h of incubation. Cells
were ﬁxed and permeabilized with Cytoﬁx/Cytoperm (BD Pharmingen) and
stained with ﬂuorescein isothiocyanate (FITC)-conjugated antibody to IFN-g
(clone XMG1.2, eBioscience), and PE-conjugated antibody to IL-4 (clone 11B11,
eBioscience). Quantitative ﬂow cytometry was performed on an Epics XL-MCL
(Beckman Coulter) or FACS Calibur (BD Bioscience).
Fractionation and western blot. Cytoplasmic and nuclear cell fractions were
prepared using ProteoExtract Subcellular Proteome Extraction kit (Calbiochem).
Western blotting was performed according to a protocol from Cell Signaling.
Anti-mouse CREB, p-CREB (S133), STAT1, and p-STAT1 (Y701) antibodies were
obtained from Cell Signaling. Anti-mouse GAPDH (6C5, Ambion), anti-mouse
a-tubulin (DM 1A, Sigma) and anti-goat lamin B (C-20, Santa Cruz) were used
as internal control. Anti-rabbit CRTC2 anti-serum has been described20.
Immunoreactive proteins were visualized by using the enhanced
chemiluminescence system from Fuji Film (LAS-3000).
Enzyme-linked immunosorbent assay. For the detection of IL-2 and IFNg
production, the supernatants of cell cultures were collected, and the manufacturer’s
instructions were followed (Pierce).
Real-time PCR. RNA puriﬁcation and reverse transcription were performed by
using Rneasy Mini Kit (Qiagen) and High-capacity cDNA Reverse Transcription
Kits (ABI), respectively. Samples were analysed by real-time PCR with FastStart
DNA MasterPLUS SYBR Green I kit or LightCycler Taqman Master kit with
Universal ProbeLibrary Set, Mouse (Roche). Primers and probes used in this study
are listed in Supplementary Table S1. Expression was normalized to that of mouse
18S ribosomal RNA (Rn18s) or glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) gene and calculated relative to expression in vehicle control by the 2–DDCt
method in each experiment.
Microarray assay. mRNA was converted to biotinylated antisense RNA using
GeneChip HT 30IVT Express Kit (Affymetrix) and biological duplicates were
hybridized to Affymetrix GenChip Mouse Genome 430 2.0 Arrays (Affymetrix).
Data were scaled, normalized by GeneChip Operating Software 1.4. After ﬁltration,
expression levels of selected probes were shown in bar graphs by using mean
intensity of biological duplicates. Microarray data were deposited in GEO Data Sets
under accession number GSE39592.
Chromatin immunoprecipitation. Freshly isolated WT CD4þ T cells were cul-
tured for 2 days in the presence of IL-7 followed by stimulation with db-cAMP
(100 mM) or vehicle for another 1 h. Cells were crosslinked with 1% (vol/vol)
formaldehyde and chromatin DNA was puriﬁed and digested by using SimpleChIP
Enzymatic Chromatin IP Kits (Cell signaling) according to the manufacturer’s
instructions. Anti-p-CREB Ser133 antibody (Cell Signaling) and anti-CRTC2 anti-
sera were used for immunoprecipitation. Precipitated DNA was quantiﬁed by real-
time PCR (primer sets in Supplementary Tables S2 and S3) and was calculated
relative to input DNA.
RNAi and nucleofection. Mouse Creb1, Crtc2 and scrambled control siRNA were
obtained from Stealth RNAi (Invitrogen). The sequence of Creb1 siRNA:
50-UUGAACAACAACUUGGUUGCUGGGC-30 (sense) or 50-GCCCAGCAACC
AAGUUGUUGUUCAA-30 (antisense); Crtc2 siRNA: 50-GCCAUGGCUCAGGA
CCUAAUAUCAU-30 (sense) or 50-AUGAUAUUAGGUCCUGAGCCAUGGC-30
(antisense). Freshly isolated CD4þ T cells were transfected with 500 pmol siRNA
using Amaxa P3 Primary Cell 4D-Nucleofector X Kit with the programme DN100
on a 4D-Nucleofector (Lonza) in 100 ml. Cells were directly transferred into full
RPMI1640, then were cultured and stimulated in the presence of IL-7. Alter-
natively, CD4þ T cells were preactivated with anti-CD3 and anti-CD28 for 2 days,
then ‘rest’ on ice for 1–2 h followed by transfecting with 5 mg plasmids in 100 ml
using Amaxa P3 Primary Cell 4D-Nucleofector X Kit with the programme EO115
on a 4D-Nucleofector (Lonza). Cells were then cultured and stimulated.
Luciferase assay. To determine the CRTC2 transcriptional activity, preactivated
CD4þ T cells were nucleofected with GAL4-fusion pM-mCRTC2 and pTAL-5x
GAL4-Luciferase reporter and pRL-TK renilla luciferase reporte as internal control
and treated with db-cAMP as indicated. To construct the mouse Il12rb2 reporter
vector, a 50-upstream fragment from  4.4 kb to þ 70 bp of the mouse Il12rb2
promoter/enhancer region were cloned by PCR and inserted into the pGL4.17
luciferase reporter vector (Promega). The sequence of primers: 5’-CTATGCTG
CTGCCTGAAAGATGAGG-3’ (forward) and 50-AGGGCACCTACCACTAT
CCTCATCC-30 (reverse). EL4 cells stably expressing the mouse Il12rb2 reporter
and the internal control renilla luciferase (Promega), EL4-Il12rb2-luc cells, were
stimulated with anti-CD3 (5 mgml 1) and db-cAMP or vehicle for 24 h, then
harvested for luciferase assay. Alternatively, EL4-Il12rb2-luc cells were transfected
with siRNA or plasmids followed by stimulation with anti-CD3 and db-cAMP as
described in the ﬁgure legend. Luciferase activities in cell lysates were detected by
The Dual-Luciferase Reporter Assay System (Promega).
CHS model. We sensitized Lck-CreEP4ﬂ/ﬂ and Lck-CreþEP4ﬂ/ﬂ mice with 25ml
of 1% (w/v) DNFB in acetone/olive oil (4/1, v/v) on shaved abdominal skin on day
0. dLN cells of one mouse were collected on day 5, and then transferred into one
naive B6 mouse. The recipient mice were immediately challenged by application of
20 ml of 0.3 or 0.5% DNFB to their ear, and ear thickness was measured with a
micrometre for each mouse before and 24 h after elicitation, and the difference
is expressed as ear swelling. Alternatively, the dLN cells were harvested from
DNFB-sensitized mice on day 5 to detect mRNA or protein expression of cytokine
receptors or were subjected to isolation of CD4þ T cells by antoMACS, and
in vitro restimulated with anti-CD3 and anti-CD28 for 24 h for measuring cytokine
production.
Colitis model. Adoptive transfer colitis model has been described43. Brieﬂy, naive
CD4þCD25CD45RBhi T cells were prepared from Lck-CreþEP4þ /þ or
Lck-CreþEP4ﬂox/þ mice by cell sorting. Cells (5 105 cells per mouse) were
transferred intravenously into mice deﬁcient in recombination-activating gene 2
(Rag2). CD4þ T cells from mesenteric lymph nodes of each recipient mouse were
puriﬁed by auto-MACS on day 42 after T-cell transfer and stimulated with anti-
CD3 for 72 h. IFN-g and IL-2 production in supernatants and gene expression
in CD4þ T cells were determined by enzyme-linked immunosorbent assay and
real-time PCR, respectively.
Data analysis. All data were expressed as mean±s.e.m., and statistical signiﬁcance
was examined by the unpaired two-tail Student’s t-test except where indicated,
using GraphPad (Prism) or Excel (Microsoft).
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